KD01(the recombinant oncolytic adenovirus)
Sponsors
Tongji Hospital
Conditions
Bladder Cancer (BC)Cervical CancerEndometrial CancerGynecologic Malignancies
Phase 1
The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies
RecruitingNCT06552598
Start: 2024-04-01End: 2028-04-01Target: 97Updated: 2026-01-15
Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)
RecruitingNCT07359235
Start: 2024-11-04End: 2028-12-31Target: 29Updated: 2026-01-22